Evidence map›Paper›PMID 35804881›Full record

ArticleCancers2022

Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.

Yurong Song, Shaneen S Baxter, Lisheng Dai, Chelsea Sanders, Sandra Burkett, Ryan N Baugher, Stephanie D Mellott, Todd B Young, Heidi E Lawhorn, Simone Difilippantonio and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Yurong SongCancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0001-7151-0575
Shaneen S BaxterCancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0001-8905-5048
Lisheng DaiCancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Chelsea SandersAnimal Research Technical Support of Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Sandra BurkettMouse Cancer Genetics Program, National Cancer Institute, Frederick, MD 21702, USA.
Ryan N BaugherCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-1658-7569
Stephanie D MellottCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Todd B YoungCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Heidi E LawhornCLIA Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Simone DifilippantonioAnimal Research Technical Support of Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Baktiar KarimMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Yuwaraj KadariyaCancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Ligia A PintoCancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Joseph R TestaCancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.ORCID 0000-0003-1301-5175
Robert H ShoemakerChemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA.
Frederick National Laboratory for Cancer Research · USFox Chase Cancer Center · USNational Cancer Institute · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
The Role of p21-Activated Kinases in Malignant MesotheliomaR01CA148805 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN, TESTA, JOSEPH R. · 2011 to 2020
$4.0M
NCI NIH HHS CA06927NCI NIH HHS CA148805NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P30 CA006927NCI NIH HHS R01 CA148805
6 · The paper itself

Abstract

Malignant mesothelioma (MMe) is a rare malignancy originating from the linings of the pleural, peritoneal and pericardial cavities. The best-defined risk factor is exposure to carcinogenic mineral fibers (e.g., asbestos). Genomic studies have revealed that the most frequent genetic lesions in human MMe are mutations in tumor suppressor genes. Several genetically engineered mouse models have been generated by introducing the same genetic lesions found in human MMe. However, most of these models require specialized breeding facilities and long-term exposure of mice to asbestos for MMe development. Thus, an alternative model with high tumor penetrance without asbestos is urgently needed. We characterized an orthotopic model using MMe cells derived from

Indexed as

biomarkercell linechromosome instabilitygenomic instabilityimmunotherapymesotheliomamicrosatellite instabilitymouse model

Identifiers

PMID35804881
PMCPMC9264972
OpenAlexW4283452915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.